×
Download 2025 Brochure
Save the Date! OPT Congress Returns to Boston March 18-19, 2025

Thank you for joining us at the 10th Annual OPT Congress.
It was great to see so many new and familiar places onsite. We look forward to welcoming you back March 18-19, 2025.


Missed this year’s Event?

Purchase On-Demand

Missed this year's event? Access content across all of this year's programs On-Demand. At your convenience, access archived presentations for On-Demand learning from anywhere, at any time.


Welcome to OPT Congress:
Oligonucleotides & mRNA Therapeutics

OPT Congress is the premier event for scientists and executive directors involved in discovering and developing oligonucleotide and mRNA therapeutics. For 2025 we are delighted to expand our content and offer a conference program dedicated to emerging oligo modalities, sharing cutting-edge research and technologies used in designing new targeted therapies. 

Now in its 10th year, this unique event brings together leading chemists, biologists, toxicologists, CMC experts, regulatory specialists and technology providers to discuss advances in next-generation therapeutics. In addition to 2 days of inspiring keynotes, breakout discussions and 95+ scientific presentations, we deliver two in-depth short courses to further add to the learning opportunities. We look forward to welcoming you to our community focused event, offering robust and customizable programming tailored to your specific needs.

 

4 Conferences
95+ Speakers
300+ Attendees
150+ Unique Organizations
2 Pre Conference Short Courses

2025 Plenary Speakers

Anastasia Khvorova, PhD

Anastasia Khvorova, PhD
Professor, RNA Therapeutic Institute, University of Massachusetts Medical School

Eric Swayze, PhD

Eric Swayze, PhD
Executive Vice President, Research, Ionis Pharmaceuticals

Edward Kaye, MD

Edward Kaye, MD
CEO and Director, Stoke Therapeutics

Ramsey Majzoub

Ramsey Majzoub, PhD
Director, Intellia Therapeutics

Our Executive Advisory Board

Mano Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Dmitry Samarsky, PhD
CSO and Board Member, GALconda Therapeutics

Chandra Vargeese, PhD
CTO & Head, Platform Discovery Sciences, Wave Life Sciences

Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences

Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

Ekkehard Leberer, PhD
Senior Life Sciences Consultant, ELBIOCON